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Abstract
Background: Although the prevalence of hypertension is higher in postmenopausal women than in premenopausal
women, little is known about changes in blood pressure (BP) during the menopausal transition. We evaluated BP
according to the menopausal transition and associated factors in healthy Korean women.
Methods: This cross-sectional study involved 2037 women aged 44 to 56 years who presented at a health-screening
center in Seoul, Korea, from November 2012 to March 2013. The association between BP and menopausal transition
and the risk factors related to elevated BP were determined using multiple linear regression analyses. Menopausal
status was divided by four groups as premenopause, early menopausal transition, late menopausal transition and
postmenopause.
Results: Both systolic and diastolic blood pressure (SBP and DBP) differed significantly according to the menopausal
status. BP showed the greatest difference between early and late menopausal transition. After adjusting for variables
related to hypertension, SBP (β = 2.753, p < 0.01) and DBP (β = 1.746, p = 0.02) were significantly higher in late than
early menopausal transition. The prevalence of hypertension was significantly different between early and late
menopausal transition (1.4 vs. 6.1 %). Waist circumference, glucose, and triglycerides were positively and
significantly associated with SBP and DBP during menopause.
Conclusions: BP and the prevalence of hypertension were significantly associated with period between early and
late menopausal transition, suggesting that changes in BP during the menopausal transition are significant. Therefore,
frequent monitoring will be needed for early detection of hypertension during the menopausal transition.
Background
Hypertension is a major contributor to morbidity and
mortality worldwide and is highly prevalent in elderly
women [1, 2]. Many cross-sectional [3–8] and longitudinal
[9–11] studies have reported a higher prevalence of hyper-
tension in postmenopausal than in premenopausal women.
However, few studies to date have evaluated changes in
blood pressure (BP) across the menopausal transition.
The menopausal transition is characterized by men-
strual cycle irregularities, changes in ovarian hormone
concentrations, and increased risk for the development
of cardiovascular disease (CVD). This transition period
can last for months or years (average, 4 years) depending
on the individual. Various menopausal symptoms, in-
cluding vasomotor, physical, psychosocial, and sexual
symptoms, appear during this time.
The Stages of Reproductive Aging Workshop (STRAW)
staging system was established for the detailed analysis of
subtle changes that occur during menopause [12]. Subtle
changes in menstrual cycle characteristics are important
early markers of the menopausal transition. The STRAW
staging system is currently used in evaluating menopausal
stage, based on changes occurring during menopause
[13–17].
Evaluating changes in BP during the menopausal tran-
sition and the factors associated with BP change is
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important because early detection of hypertension and
appropriate interventions can prevent its complications,
including stroke, myocardial ischemia, and renal dys-
function. This study was therefore designed to evaluate
differences in BP according to the menopausal transi-
tion, defined using the STRAW staging system, and to




The study population included Korean women aged 44
to 56 years who visited the health-screening centers at
the Kangbuk Samsung Hospitals in Seoul and Suwon
between November 2012 and March 2013. This cross-
sectional study was designed to investigate the attitudes
of Korean women towards menopause. Women diagnosed
with or treated for serious diseases, such as cancer, were
excluded during screening. Of the 2204 women deemed
eligible, three were excluded from analysis because their
age was more than 56 years. The study sample therefore
consisted of 2201 women. Of these 2201 women, 164 were
taking antihypertensive drugs. Therefore, factors related to
hypertension were examined in all 2201 women and
factors associated with SBP and DBP were analyzed in the
2037 women not taking antihypertensive drugs. The study
protocol was approved by the institutional review board of
Kangbuk Samsung Hospital, and all participants provided
written informed consent before enrollment.
Measurements
The BP of each participant was measured three times by
trained nurses using automatic BP equipment (53000-E2,
Welch Allyn, USA) after a 5 min rest. The final BP was
calculated by averaging the values from the second and
third BP measurements. Hypertension was defined as
SBP ≥140 mmHg and DBP ≥90 mmHg.
The subjects were divided into four categories accord-
ing to menopausal status, based on STRAW stage [12].
The premenopausal period was defined as having regular
menstrual periods; early menopausal transition was de-
fined as two or more cycles of ≥7 days difference in cycle
length; late menopausal transition was defined as two
skipped cycles and an interval of amenorrhea ≥60 days;
and postmenopause was defined as the period after 12
consecutive months of amenorrhea.
Subjects were administered the Korean version of the
Menopause-Specific Quality of Life (MENQOL) ques-
tionnaire. This questionnaire divided menopausal symp-
toms into four domains: vasomotor (3 items), psychosocial
(7 items), physical (16 items), and sexual (3 items) [18, 19].
Each item has a score ranging from 0 (not at all bothered)
to 6 (extremely bothered). The average score of each
domain was calculated.
Body mass index (BMI) was defined as weight in
kilograms divided by height in meters squared. Waist
circumference (WC) was measured at the midpoint
between the lower ribs and the top of the iliac crest in
the standing position. Smoking status was categorized
as having or not having a direct lifetime experience of
smoking.
Blood samples were collected after a ≥10 h fast. Glucose,
high-density lipoprotein cholesterol (HDL-cholesterol),
low-density lipoprotein cholesterol (LDL-cholesterol), and
triglyceride levels were measured enzymatically (Module
Extention D2400, Roche, Japan). The homeostatic model
for insulin resistance (HOMA-IR) was calculated as fasting
insulin (μIU/mL) × fasting glucose (mg/dL)/(22.5 × 18).
Serum levels of uric acid and gamma-glutamyltransferase
(GGT) were measured using an automated clinical chemis-
try analyzer (Modular DP analyzers: Roche Diagnostics,
Tokyo, Japan). Serum free triiodothyronine (FreeT3) levels
were measured using an electrochemiluminescent im-
munoassay (Roche E170) with a lower limit of detection of
0.26 pg/mL. The normal range for FreeT3 was 2.0–4.4 pg/
mL, with a total variation of 2.5–3.2 % at low concentra-
tions and 2.6–3.3 % at high concentrations.
Statistical analysis
Continuous variables are reported as mean ± standard
deviation (SD), and categorical data as frequency and
percentage. One-way analysis of variance (ANOVA) and
the chi-square test were used for unadjusted compari-
sons of demographic, physical, and biochemical charac-
teristics in the four menopausal status groups. The
analysis of covariance (ANCOVA) test was used to
compare differences in age-adjusted BP according to the
menopausal transition. Factors associated with elevated
BP and the prevalence of hypertension according to
menopausal status were evaluated by multiple linear re-
gression and logistic regression analyses with variable se-
lection using backward elimination, respectively. Linear
regression coefficients are shown as unstandardized.
Statistical tests were two-sided, and p <0.05 was consid-
ered statistically significant. All statistical analyses were
performed using SPSS version 21.0 (SPSS Inc., Chicago,
IL, USA).
Results
The mean age of the 2201 subjects was 48.8 ± 3.5 years.
Unadjusted comparisons of baseline characteristics ac-
cording to menopausal status are presented in Table 1.
Of study population, 809 (36.8 %) were premenopausal,
317 (14.4 %) were in early menopausal transition, 414
(18.8 %) were in late menopausal transition, and 661
(30.0 %) were postmenopausal. For analysis of SBP and
DBP according to menopausal status (2038 subjects),
775 (38.1 %) were premenopausal, 296 (14.5 %) were in
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early menopausal transition, 380 (18.7 %) were in late
menopausal transition, and 586 (28.8 %) were post-
menopausal. The baseline characteristics of these sub-
jects are listed in Additional file 1. Age, BMI, WC,
SBP, DBP, hypertension, menopausal symptoms, glu-
cose, LDL-cholesterol, triglycerides, GGT, FreeT3, and
uric acid differed significantly according to meno-
pausal status (p <0.05). Menopausal status was not
significantly associated with smoking, HDL-cholesterol
concentration, and HOMA-IR score. Both SBP and
DBP differed significantly among these four groups,
particularly from early to late menopausal transition.
Hypertension was about 9.8 % more prevalent in pre-
menopause than in postmenopause. The difference
was greatest between early and late menopausal transi-
tion (approximately 5.8 %). The difference in SBP/DBP
between premenopause and postmenopause was 2.3/
1.3 mmHg, and that between early and late meno-
pausal transition was 3.4/2.9 mmHg. Age-adjusted SBP
and DBP in late menopausal transition were 2.8 and
2.5 mmHg higher, respectively, than in early menopausal
transition (p <0.05). The prevalence of hypertension was
also significantly associated with menopausal status, par-
ticularly between early and late menopausal transition
(7.9 vs. 13.7 %).
Table 2 shows the results of simple and multiple linear
regression analysis to identify the relationships between
blood pressure and menopausal status. After adjusting
for variables related to hypertension, SBP (β = 2.753,
p<0.01) and DBP (β = 1.746, p = 0.02) were significantly
different between early and late menopausal transition,
while there was no significant difference either between
premenopause and early menopausal transition or be-
tween late menopausal transition and postmenopause.
SBP was also significantly associated with WC, physical
symptoms, glucose, LDL-cholesterol, triglycerides and
HOMA-IR, whereas DBP was significantly associated
with WC, vasomotor symptoms, psychosocial symptoms,
Table 1 Baseline characteristics of the study population
Premenopause Menopausal transition Postmenopause P-value
Variable (n=809) Early (n=317) Late (n=414) (n=661)
Age, year 46.8±2.5 47.5±2.4 49.6±2.8 52.2±3.1 <.001
BMI, kg/m2 23.0±3.1 22.8±3.0 23.0±3.1 23.4±3.1 0.006
WC, cm 78.3±7.8 78.2±7.2 78.9±8.0 80.1±8.0 <.001
Smoking, n (%) 24(4.2) 6(2.7) 10(3.5) 19(4.3) 0.734
SBP, mmHga 102.9±12.5 102.6±11.3 106.0±13.7 105.2±12.2 <.001
DBP, mmHga 66.9±9.7 66.2±8.7 69.1±10.3 68.2±9.3 <.001
Hypertension, n (%)
Normal 683(84.6) 261(82.3) 305(74.4) 490(74.5) <.001
Prehypertension 71(8.8) 31(9.8) 49(12.0) 73(11.1)
Hypertension 53(6.6) 25(7.9) 56(13.7) 95(14.4)
Menopause symptoms, score (0–6)
Vasomotor 0.5±0.9 0.7±1.0 1.1±1.4 1.6±1.6 <.001
Psychosocial 1.1±1.1 1.4±1.2 1.6±1.3 1.8±1.4 <.001
Physical 1.5±1.0 1.8±1.1 1.9±1.2 2.0±1.2 <.001
Sexual 1.1±1.3 1.5±1.5 1.8±1.7 2.5±1.9 <.001
Glucose, mg/dL 95.1±13.6 94.2±15.7 96.5±16.9 96.8±15.1 0.032
HDL-cholesterol, mg/dL 63.1±14.7 63.8±14.8 64.5±15.7 62.3±15.7 0.100
LDL-cholesterol, mg/dL 117.3±28.3 118.1±29.0 128.2±33.3 131.9±32.1 <.001
Triglycerides, mg/dL 90.2±53.9 93.0±56.1 97.5±58.9 102.2±54.6 <.001
HOMA-IR 1.5±1.1 1.4±0.9 1.3±1.0 1.5±1.1 0.121
GGT, U/L 19.1±24.7 18.0±14.6 20.9±22.3 25.1±30.1 <.001
FreeT3, pg/mL 2.8±0.4 2.9±0.3 2.9±0.4 3.0±0.4 <.001
Uric acid, mg/dL 4.1±0.8 4.0±0.8 4.3±0.9 4.4±0.9 <.001
Continuous variables are reported as mean±SD and compared by ANOVA; categorical variables are reported as n (%) and compared by the chi-square test
Abbreviations: BMI body mass index; WC waist circumference; SBP systolic blood pressure; DBP diastolic blood pressure; GGT gamma-glutamyltransferase; FreeT3
free triiodothyronine
aThe numbers of premenopause, early menopausal transition, late menopausal transition and postmenopause for SBP and DBP were 775, 296, 380 and
586, respectively
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glucose, HDL-cholesterol, LDL-cholesterol and triglycer-
ides after adjustment and variable selection.
Factors associated with increased risk of hypertension
were evaluated by multiple logistic regression analyses with
variable selection using backward elimination (Table 3).
After adjustment for covariates, hypertension was also sig-
nificantly associated only with the period from early to late
menopausal transition (OR=1.877, 95 % CI=1.009–3.495).
Moreover, hypertension was significantly associated with
WC, glucose, LDL-cholesterol, HOMA-IR and uric acid.
Discussion
To our knowledge, this is the first study to investigate
differences in BP according to the menopausal transition
and the factors associated with BP as a function of
menopausal status according to the STRAW staging sys-
tem in healthy Korean women. The study population
consisted of women aged 44–56 years, the age range
during which the risks of hypertension increase mark-
edly in women [20, 21].
Our findings, that BP and hypertension were signifi-
cantly associated with menopausal status, were consist-
ent with previous reports [3–11]. We found that most of
the difference in BP occurred during the menopausal
transition, i.e., from early to late menopausal transition.
Differences in SBP and DBP (as well as difference of
prevalence of hypertension) between early and late meno-
pausal transition were the greater than at other periods
Table 2 Results of simple and multiple linear regression analysis using SBP and DBP as the dependent variable
Univariate Multivariate
Β (S.E.) P-value Β (S.E.) P-value
(a) SBP
Menopausal status
Early menopausal transition vs. Premenopause −0.310(0.853) 0.72 −0.320(0.832) 0.70
Late vs. Early menopausal transition 3.443(0.969) <0.01 2.753(0.960) <0.01
Postmenopause vs. Late menopausal transition −0.819(0.824) 0.32 −1.406(0.830) 0.09
WC 0.482(0.034) <0.01 0.316(0.041) <0.01
Menopause symptoms
Physical 0.070(0.241) 0.77 −0.491(0.242) 0.04
Glucose 0.222(0.021) <0.01 0.101(0.024) <0.01
HDL-cholesterol −0.080(0.018) <0.01 0.035(0.020) 0.09
LDL-cholesterol 0.075(0.009) <0.01 0.045(0.009) <0.01
Triglycerides 0.050(0.005) <0.01 0.019(0.006) <0.01
HOMA-IR 3.385(0.285) <0.01 1.141(0.371) <0.01
FreeT3 3.088(0.795) <0.01 1.428(0.756) 0.06
(b) DBP
Menopausal status
Early menopausal transition vs. Premenopause −0.669(0.654) 0.31 −0.468(0.632) 0.46
Late vs. Early menopausal transition 2.875(0.743) <0.01 1.746(0.727) 0.02
Postmenopause vs. Late menopausal transition −0.885(0.633) 0.16 −1.199(0.616) 0.06
WC 0.259(0.027) <0.01 0.176(0.029) <0.01
Menopause symptoms
Vasomotor 0.565(0.160) <0.01 0.524(0.197) <0.01
Psychosocial −0.064(0.168) 0.70 −0.619(0.200) <0.01
Glucose 0.132(0.016) <0.01 0.078(0.016) <0.01
HDL-cholesterol −0.035(0.014) 0.01 0.043(0.015) <0.01
LDL-cholesterol 0.049(0.007) <0.01 0.027(0.007) <0.01
Triglyceride 0.036(0.004) <0.01 0.024(0.004) <0.01
Abbreviations: WC waist circumference; SBP systolic blood pressure; DBP diastolic blood pressure; GGT gamma-glutamyltransferase; FreeT3 free triiodothyronine;
Univariate simple linear regression for each independent variable; Multivariate multiple linear regression adjusted by menopausal status, WC, Age, vasomotor
symptom, psychosocial symptom, physical symptom, sexual symptom, glucose, HDL-cholesterol, LDL-cholesterol, triglyceride, HOMA-IR, GGT, FreeT3, and uric acid
with variable selection using backward elimination(significance level for stay=0.15); β non-standardized coefficients of each linear regression analysis; S.E. standard
error of β
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during menopause. Although the finding that BP in-
creased by 2.8/2.5 mmHg through menopausal transition
is seemingly small and within normal limits, the period
between early and late menopausal transition can last for
months or years. Also, since the study population com-
prised usually healthy women, BP differences in the
general population may be greater than in the study popu-
lation. In terms of menopausal status, multiple linear and
logistic regression analyses found that SBP, DBP, and the
prevalence of hypertension differed significantly only from
early to late menopausal transition after adjusting for
covariates related to hypertension. There was no signifi-
cant difference in BP between late menopausal transition
and postmenopause. Because we included women aged
less than 57 years, it is possible that postmenopausal
women were in a relatively early postmenopausal state.
Although BP and hypertension are significantly higher
in postmenopausal than in premenopausal women [3–11],
the direct relationship between the menopausal transition
and blood pressure is unclear. Studies have suggested that
the relationship between menopause and hypertension is
due to other factors, including age and BMI [6, 22, 23].
Moreover, a study in African-American and White women
reported no difference in BP change over a 6 year period
among women who did and did not undergo the meno-
pausal transition [24]. The SWAN (Study of Women’s
Health Across the Nation) study showed that menopausal
transition had no effect on BP after adjusting for age
and other confounders [25]. To clarify the relationship
between hypertension and menopausal status, we iden-
tified confounding factors associated with hypertension.
Age, BMI, WC, vasomotor symptom, glucose, HDL-
cholesterol, LDL-cholesterol, triglycerides, HOMA-IR,
GGT, and uric acid (Additional file 2) were significantly
associated with hypertension. We therefore adjusted for
these covariates in analyzing the relationship between
BP and menopause. In addition, previous studies cate-
gorized menopausal status into two or three groups,
such as premenopause and postmenopause or preme-
nopause, perimenopause, and postmenopause [3–11,
22–24]. By contrast, we divided menopausal status into
four groups according to the STRAW staging system.
The mechanisms by which BP increases after meno-
pause have not been well-characterized. Estrogen defi-
ciency during menopause may induce endothelial and/or
vascular dysfunction through reduced compliance of the
large arteries [21]. Menopause has also been associated
with weight gain and increases in circulating insulin
concentrations [4, 7, 9, 26–28]. Estrogen deficiency
during menopause may affect the balance among various
vasoactive hormones and the proliferation and function
of vascular smooth muscle cells, possibly by altering the
electrolyte composition of the intra- or extra-cellular
milieu [21]. In addition, menopause is characterized by a
redistribution of body sodium and the cessation of the
menses, followed by increases in hemoglobin levels and
erythrocyte counts [29]. This increase in blood viscosity
after menopause may also increase BP [30, 31]. Hormo-
nal instability usually occurs during the menopausal
transition: in particular, estrogen levels can vary greatly
during that time. A cross-sectional study showed that
estrogen levels fell markedly during the late menopausal
transition [32]; thus, BP may increase, particularly dur-
ing menopausal transition period.
To summarize, the main findings of this study suggest
that the association between BP and menopausal status
was significant only for the menopausal transition period.
BP and hypertension were positively and significantly
Table 3 The effect of menopausal transition on hypertension
Univariate P-value Multivariate P-value
Menopausal status
Early menopausal transition vs. Premenopause 1.218(0.743–1.997) 0.43 1.168(0.639–2.136) 0.61
Late vs. Early menopausal transition 1.848(1.125–3.035) 0.02 1.877(1.009–3.495) 0.04
Postmenopause vs. Late menopausal transition 1.067(0.747–1.523) 0.72 0.801(0.507–1.264) 0.34
WC 1.067(1.049–1.084) <0.01 1.036(1.011–1.060) <0.01
Menopause symptoms
Vasomotor 1.179(1.079–1.290) <0.01 1.125(0.999–1.267) 0.06
Glucose 1.028(1.020–1.035) <0.01 1.014(1.005–1.024) <0.01
LDL-cholesterol 0.999(0.994–1.003) 0.57 0.992(0.986–0.997) <0.01
HOMA-IR 1.563(1.397–1.749) <0.01 1.186(1.013–1.389) 0.03
Uric acid 1.575(1.361–1.823) <0.01 1.345(1.103–1.642) <0.01
Data reported as odds ratio (95 % confidence interval)
Abbreviations: WC waist circumference; SBP systolic blood pressure; DBP diastolic blood pressure; GGT gamma-glutamyltransferase; FreeT3 free triiodothyronine;
Univariate simple logistic regression for each independent variable; Multivariate multiple logistic regression adjusted by menopausal status, age, WC, smoking,
vasomotor symptom, psychosocial symptom, physical symptom, sexual symptom, glucose, HDL-cholesterol, LDL-cholesterol, triglyceride, HOMA-IR, GGT, FreeT3,
and uric acid with variable selection using backward elimination (significance level for stay=0.15)
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associated with WC and glucose after adjustment for vari-
ables related to hypertension. The study population com-
prised usually healthy women. Vasomotor symptoms
related only to DBP, not to SBP and hypertension. Also,
LDL-cholesterol was a negative independent predictor of
hypertension after adjusting for variables related to hyper-
tension. These confusing results could be made clearer if
the study population was randomly selected and the statis-
tical power stronger.
This study had several limitations. First, since the sur-
vey was cross-sectional, a cause-and-effect relationship
could not be identified between increased blood pressure
and menopausal transition. Second, subjects were re-
cruited from health-screening centers at two hospitals in
Seoul and Suwon, suggesting that our findings may not
be generalized to all middle-aged women in Korea.
Finally, although we sought to control for potential con-
founding factors that could affect the BP, our results
may have been influenced by other, as yet unknown
factors.
Nevertheless, our study had several strengths, includ-
ing its relatively large sample size compared with previ-
ous studies. Furthermore, our study investigated BP, the
prevalence of hypertension, and their predictors adjusted
for factors associated with hypertension, including meno-
pausal symptoms, in healthy middle-aged Korean women
according to menopausal status criteria defined according
to the STRAW staging system.
Conclusions
In conclusion, the present study showed that BP was sig-
nificantly associated with menopausal transition. A pre-
vious study showed that elevated BP is an independent
risk factor for all cause mortality, as well as for cardio-
vascular disease-related mortality [33]. These findings
suggest the need of frequent BP monitoring during the
menopausal transition, perhaps resulting in earlier detec-
tion and treatment of hypertension may be reduced in
postmenopausal women. Further prospective studies are
needed to confirm our findings on BP changes and the
factors influencing these changes during the menopausal
transition.
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